Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

UNITED THERAPEUTICS (UTHR) EBIT Margin: 2009-2024

Historic EBIT Margin for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to 47.86%.

  • UNITED THERAPEUTICS's EBIT Margin rose 278.00% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 1621.00%. This contributed to the annual value of 47.86% for FY2024, which is 305.00% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its EBIT Margin stood at 47.86% for FY2024, which was down 6.00% from 50.91% recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's EBIT Margin ranged from a high of 50.91% in FY2023 and a low of 32.98% during FY2021.
  • Its 3-year average for EBIT Margin is 49.79%, with a median of 50.60% in 2022.
  • Per our database at Business Quant, UNITED THERAPEUTICS's EBIT Margin soared by 5,297bps in 2020 and then slumped by 704bps in 2021.
  • UNITED THERAPEUTICS's EBIT Margin (Yearly) stood at 40.02% in 2020, then slumped by 704bps to 32.98% in 2021, then spiked by 1,762bps to 50.60% in 2022, then spiked by 31bps to 50.91% in 2023, then plummeted by 305bps to 47.86% in 2024.